Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats

Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Lesovaya, Ekaterina A., Kirsanov, Kirill I., Antoshina, Elena E., Trukhanova, Lubov S., Gorkova, Tatiana G., Shipaeva, Elena V., Salimov, Ramiz M., Belitsky, Gennady A., Blagosklonny, Mikhail V., Yakubovskaya, Marianna G., Chernova, Olga B.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Gerotarget (Focus on Aging): Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4496392/
https://ncbi.nlm.nih.gov/pubmed/25991667
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados